Cannabis Company Forms Partnership to Develop Pharmaceuticals
Source: Streetwise Reports
October 9, 2017 (Investorideas.com Newswire) Analyst Russell Stanley with Echelon Wealth Partners explained the significance of the recent licensing agreement signed by this Canadian medical marijuana producer and distributor.
In an Oct. 4 research note, Russell Stanley, an analyst with Echelon Wealth Partners, reported that Emblem Corp. (EMC:TSX.V) entered into an exclusive licensing arrangement with the private company Canntab Therapeutics Ltd. to collaborate on "preclinical formulation, clinical development, regulatory approval, manufacturing and commercialization" of Canntab's "patent-pending oral sustained release formulation for cannabinoids."
About the event, Stanley concluded, "We view this as a positive step towards developing pharmaceutical applications for cannabis, which is a major pillar of [Emblem's] strategy." The company's other two areas of focus are advancing marijuana production and health care services.
Under the agreement, Emblem will have "exclusivity in Canada with respect to Canntab's intellectual property and know-how and would sell the product under the Emblem brand (though the agreement does not include import/export rights)," described the analyst. Either firm could handle manufacturing.
As for the financial component, Emblem must make "milestone payments to Canntab based on completion of stability studies, bioavailability studies and regulatory approval" and, eventually, "royalty payments based on gross product sales," Stanley said.
The major advantage to Canntab's product is that it is sustained release, Stanley indicated. It is "believed to release the cannabinoid content over a period of 12+ hours," he added. "This allows for maintaining a constant drug concentration over a specific period of time, generally with the aim of improving therapeutic outcomes and/or patient compliance."
This compares to "most existing dosage forms," Stanley said, which "release the active drug component right away." As such, these immediate release therapeutics "tend to lose their effect in four to six hours, necessitating frequent dosing, which can impede patient compliance."
Stanley commented on the potential market for such a cannabis pharmaceutical. The sustained release feature makes it "particularly suited to managing chronic pain, which represents a $500 million a year market and affects 2 million Canadians," he said.
Further, according to surveys, "almost 80% of current medical cannabis prescriptions" are for chronic pain management," noted Stanley, "however less than 10% of physicians in Canada actively prescribe cannabis." This suggests that "a product that supports stronger patient compliance could help improve physician penetration and broaden the medical cannabis market's reach."
Echelon has a Speculative Buy rating and $2.25 per share price target on Emblem, whose stock is trading currently at around $1.98 per share.
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a sponsor of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article. As of the date of this interview, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Emblem Corp., a company mentioned in this article.
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release on the Investorideas.com newswire http://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.